Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01528644
Other study ID # BBSRC grant:BB/G0055833/1
Secondary ID 2011/2012-05
Status Completed
Phase N/A
First received January 17, 2012
Last updated February 28, 2013
Start date February 2012
Est. completion date January 2013

Study information

Verified date February 2013
Source University of East Anglia
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

Iron deficiency anaemia affects around two billion people worldwide. Food fortification with iron is a realistic way to combat this problem. Water soluble forms of iron are considered to be more bioavailable than nonsoluble iron compounds. However, the former often cause sensory problems when added to foods, while the latter cause fewer problems but are not generally well absorbed and are therefore ineffective as fortificants. A potential strategy for overcoming this problem is the use of water soluble iron compounds protected by a water resistant barrier, which will prevent potential organoleptic changes within fortified foods and protect the iron (from oxidation) through the digestion process thus increasing its availability. The investigators will use alginate, in the form of alginate beads, as a protective barrier for soluble iron gluconate. It has been shown that alginates bind divalent and trivalent cations and therefore may be a useful vehicle for soluble iron compounds to fortify foods.

The aim of this project is to measure the effect of alginate on iron absorption from ferrous gluconate and assess the potential modulating effect of calcium on iron absorption in the presence and absence of alginate.


Description:

This study is a randomised, single blinded, cross-over trial with participants randomly allocated into two groups: A (n= 8 volunteers) and B (n=8 volunteers). The study will include a total of four arms.

By administration of test meals #1 (iron in alginate beads) and #4 (iron in a capsule) the possible protective effect of alginate on iron absorption will be investigated. By administration of test meal #2 (iron in alginate beads + calcium capsule)and #3 (iron in a capsule + calcium in a capsule)the study will investigate whether alginates can bind calcium (a well-known iron inhibitor) in vivo, thus diminish the potential negative effect of calcium on iron absorption.

Only half (8) of the volunteers will undergo treatments including calcium. Therefore group A will undergo all 4 tests, whereas group B will undergo 2 out of 4 tests.

The four test meals will be administered a week apart following an overnight fast. On each occasion blood sampling will take place over a period of 6h with samples taken via a cannula at t=0, 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Serum samples will be analysed for iron content allowing calculation of iron absorption.

The assumptions made for the power calculation to estimate the number of volunteers are that a difference of 2.5% in iron absorption in the presence and absence of alginate ( test meal #1 and test meal #4) will be nutritionally significant. A minimum of 12 volunteers would be required to complete the study to detect a difference of 2.5% at a significance level of 0.05 for 80% power. A minimum of 8 volunteers would be required to detect a significant difference in iron absorption of 3.3% between a test meal containing 20mg of iron as iron gluconate with calcium and a test meal containing 20mg of iron as iron gluconate with calcium and alginate beads (test meals #2 and #3). This assumes a power of 80%, a level of significance of 0.05 and standard deviation of differences (within pairs) of 2.8%


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date January 2013
Est. primary completion date November 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Apparently healthy women (aged 18-45) or male blood donors (aged 18-65)

- Serum ferritin value of =15 = 60µg/L

- BMI >18.5 or < 30

- Willingness to consume jelly prepared with the use of gelatine from an animal source.

Exclusion Criteria:

- Diagnosed with a long-term illness requiring active treatment, e.g. diabetes, cancer, cardiovascular disease

- Currently smoking or stopped smoking in the last 12 months

- Previous or current GI disease

- Any significant co-morbidity

- Previous GI surgery

- Blood donation within the previous 3 months assuming that volume taken is above 500ml in a 4-month period

- Blood transfusion within the last 3 months

- The results of the screening tests indicate unsuitability to take part in the study

- Related to someone in the study team i.e. spouse, partner or immediate family member

- Regular prescribed medication that may interfere with iron metabolism

- Regular use of antacids and laxatives (at least once a week)

- Women who are pregnant or less than 12 months since giving birth

- Women who are breast feeding

- Vitamin supplements with or without minerals if taken more than once a week, and unwillingness to discontinue occasional use for the duration of study

- Unwillingness to discontinue use of herbal supplements for the duration of study

- Unwillingness to consume jelly prepared with animal source gelatine

- Use of antibiotics within four weeks prior to study start Parallel participation in another study which involves dietary interventions or sampling of blood that may increase the volume taken above 500ml in a 4-month period

- Asthma requiring treatment within the last two years

- Results of clinical screening which indicate a health problem which could compromise the well-being of the volunteer if they participated or which would affect the study data.

Study Design

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
alginate beads containing ferrous gluconate
After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 3 placebo capsules (each containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
ferrous gluconate in a capsule
After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule and 2 placebo capsules (each containing 50mg of dextrose) followed by a cola jelly (200ml)and cola drink (200ml) will be given to the volunteer. Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
ferrous gluconate in a capsule in presence of calcium
After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule together with 2 calcium capsules (each containing 300mg of calcium phosphate)followed by cola jelly (200ml) and cola drink(200ml)will be given to the volunteer . Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
alginate beads with ferrous gluconate in presence of calcium
After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 2 calcium capsules (each containing 300mg of calcium as calcium phosphate, 1 placebo capsule (containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.

Locations

Country Name City State
United Kingdom Clinical Research and Trials Unit (CRTU)/ Norfolk and Norwich University Hospital (NNUH) Norwich Norfolk

Sponsors (2)

Lead Sponsor Collaborator
University of East Anglia Institute of Food Research

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in iron absorption Iron absorption (by measuring iron appearance in the serum)will be measured on four occasions with a week in between each measurement. Absorption will be assessed in response to four test meals as follows: unprotected ferrous gluconate, iron gluconate incorporated into alginate beads,ferrous gluconate incorporated into alginate beads given with calcium, and unprotected ferrous gluconate given with calcium. Four weekly measurements over a period of three weeks (6h Cannulation, baseline blood sample (t=0). Test meal 1, followed by blood sample collection at 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Removal of the cannula) No
See also
  Status Clinical Trial Phase
Completed NCT01483768 - Study of Sleeve Gastrectomy on Iron Intestinal Absorption in Morbidly Obese Patients N/A
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Recruiting NCT02242188 - Supplementing Iron and Development in Breastfed Infants (SIDBI Study) Phase 4
Completed NCT02714361 - A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women N/A
Completed NCT02176759 - Iron Absorption From Rice Fortified With Ferric Pyrophosphate N/A
Completed NCT01922479 - Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure Phase 4
Completed NCT01991626 - Evaluation of the Effects of an Exogenous Phytase on Iron Absorption From LNS Added to Complementary Foods N/A
Completed NCT01687062 - Iron Absorption From Tef-injera in Women of Reproductive Age N/A
Completed NCT01573013 - Iron Fortification Trail Using NaFeEDTA in Iron Deficient Lead-exposed Children N/A
Completed NCT01191463 - The Efficacy of a Local Vitamin-C Rich Fruit (Guava) in Improving Iron Absorption From Mungbean Based Meals and Its Effect on Iron Status of Rural Indian Children (6-10 Years) N/A
Completed NCT01443832 - Iron Absorption From Iron-fortified Fonio Porridge: a Stable Isotope Study Phase 0
Completed NCT01061307 - An Efficacy Trial of Iron, Zinc and Vitamin A Fortified Rice in Children in Satun, Thailand Phase 0
Not yet recruiting NCT00515918 - The Effect of Early Iron Deficiency on Developmental Brain and Behavior in Infants N/A
Recruiting NCT00378469 - Study of the Effects of Muscular Activity on Iron Metabolism N/A
Recruiting NCT05992116 - Iron Deficiency in Patients With Heart Failure and Reduced and Mildly Reduced Ejection Fraction
Completed NCT05262634 - Pregnancy Outcome in Women With an Iron Deficiency in the First Trimester
Completed NCT06080555 - Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia Phase 1
Completed NCT04602247 - Evaluation of Iron Bioavailability From Iron Chlorophyllin N/A
Completed NCT02996786 - Effects of Danggui Buxue Tang on Blood Biochemical Parameters in Male Recreational Runners N/A
Completed NCT02175888 - The Optimization of Bioavailability From Iron Supplements: Study 1 N/A